Generate Biomedicines (NASDAQ:GENB) Stock Falls 6% – Here’s Why

Shares of Generate Biomedicines Inc (NASDAQ:GENB) dropped 6% during mid-day trading on Tuesday. The company traded as low as $12.95 and last traded at $13.01. Approximately 225,037 shares traded hands during trading, a decline of 73% from the average daily volume of 843,769 shares. The stock had previously closed at $13.84.

Analyst Upgrades and Downgrades

GENB has been the subject of a number of research reports. Wall Street Zen raised shares of Generate Biomedicines from a “sell” rating to a “hold” rating in a research note on Saturday, September 26th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Generate Biomedicines in a report on Monday, October 5th. Finally, Weiss Ratings upgraded shares of Generate Biomedicines from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 25th. Six equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus price target of $26.40.

Generate Biomedicines Stock Performance

The firm’s 50-day moving average price is $15.56 and its two-hundred day moving average price is $14.43. The firm has a market capitalization of $1.66 billion and a price-to-earnings ratio of -8.12.

Generate Biomedicines (NASDAQ:GENB) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($0.52) earnings per share for the quarter, missing the consensus estimate of ($0.48) by ($0.04). The business had revenue of $6.31 million for the quarter. As a group, equities research analysts anticipate that Generate Biomedicines Inc will post -2.29 EPS for the current year.

Hedge Funds Weigh In On Generate Biomedicines

Several hedge funds have recently added to or reduced their stakes in the stock. State Street Corp acquired a new stake in shares of Generate Biomedicines during the second quarter worth about $8,883,000. The Manufacturers Life Insurance Company bought a new stake in shares of Generate Biomedicines in the 2nd quarter valued at about $1,431,000. Squarepoint Ops LLC acquired a new stake in Generate Biomedicines in the 2nd quarter valued at about $530,000. AXQ Capital LP bought a new stake in Generate Biomedicines in the second quarter valued at approximately $218,000. Finally, Braidwell LP acquired a new position in shares of Generate Biomedicines in the second quarter valued at $55,398,000.

About Generate Biomedicines

Generate Biomedicines is a biotechnology company focused on discovering and developing protein-based medicines. The company uses generative artificial intelligence, machine learning and laboratory-based biological research to design new therapeutic proteins and identify candidates with potential applications in a range of diseases.

Its platform, often described as a generative biology approach, is designed to model biological systems and create proteins with desired characteristics rather than relying solely on modifying naturally occurring molecules.